This document summarizes Dr. Anil Pareek's clinical research initiatives at Ipca Laboratories Ltd. focusing on three key areas: 1) Developing Aceclofenac to fulfill a safety need for NSAIDs, 2) Conducting studies on Chlorthalidone to establish it as an evidence-based diuretic for hypertension, and 3) Approval of Hydroxychloroquine as the first anti-inflammatory drug for type 2 diabetes by linking diabetes and inflammation. The document outlines various clinical trials conducted on these drugs that established their efficacy and safety.